异质性万古霉素耐药金黄色葡萄球菌感染研究进展(3)
 |
| 第1页 |
参见附件(2134KB，3页)。
[8] Utaida, S., R. F. Pfeltz, R. K. Jayaswal, and B. J. Wilkinson. 2006. Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. Antimicrob. Agents Chemother,50:1541-1545.
[9] Sieradzki, K., and A. Tomasz. 2003. Alterations of cell wall structure and 136 HOWDEN ET AL. CLIN. MICROBIOL. REV.Downloaded from cmr.asm.org at Univ of Idaho on January 22, 2010 metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol,185:7103-7110.
[10] Koehl, J. L., A. Muthaiyan, R. K. Jayaswal, K. Ehlert, H. Labischinski, and B. J. Wilkinson. 2004. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother,48:3749-3757.
[11] Nelson, J. L., K. C. Rice, S. R. Slater, P. M. Fox, G. L. Archer, K. W. Bayles, P. D. Fey, B. N. Kreiswirth, and G. A. Somerville. 2007. Vancomycinintermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob. Agents Chemother. 51:616-622.
[12] Sakoulas G,Moellering RC Jr,Eliopoulos GM.Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.Clin.Infect.Dis,2006,42:40-50.
[13] Wootton M, Avison MB,Bennett PM,et al. Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin and hetero-VISA.J antimicrob Chemother,2004,53(2):406-407 ......
您现在查看是摘要介绍页，详见PDF附件(2134KB，3页)。